People: Synageva BioPharma Corp (GEVA.O)

GEVA.O on Nasdaq

95.46USD
19 Dec 2014
Price Change (% chg)

$0.46 (+0.48%)
Prev Close
$95.00
Open
$94.80
Day's High
$98.38
Day's Low
$94.08
Volume
499,096
Avg. Vol
243,402
52-wk High
$119.42
52-wk Low
$60.19

Search Stocks

Davis, Stephen 

Brief Biography

Mr. Stephen R. Davis is Independent Director of Synageva BioPharma Corp., since June 2007. In May 2013, Mr. Davis joined Heron Therapeutics, Inc. (formerly known as A.P. Pharma), a publicly traded company, as Executive Vice President and Chief Operating Officer and has served as a member of Heron Therapeutics’ board of directors since June 2012. Previously, Mr. Davis was Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. He has completed numerous strategic transactions between biotechnology and pharmaceutical companies, including the recent $1.26 billion acquisition of Ardea by AstraZeneca PLC. Prior to Ardea, Mr. Davis served as President and Chief Executive Officer of Neurogen Corporation, a biopharmaceutical company acquired by Ligand Pharmaceuticals. Before becoming Neurogen’s Chief Executive Officer, Mr. Davis served in numerous executive roles at Neurogen completing multiple collaboration and asset acquisition and sale transactions with global pharmaceutical companies. Mr. Davis is also a director of Furiex Pharmaceuticals Inc., a publicly traded biotechnology company. Previously, Mr. Davis practiced as a corporate and securities attorney with a Wall Street law firm and as a Certified Public Accountant with a major accounting firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University. Mr. Davis has extensive knowledge of the Company’s industry, as evidenced by his professional background. The Board of Directors benefits from Mr. Davis’ experience in several senior positions at biopharmaceutical corporations and particular expertise in corporate finance.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Felix Baker

--

Sanj Patel

3,878,120

Carsten Boess

1,513,440

Robert Bazemore

--

Anthony Quinn

1,566,510

Ulrich Goldmann

--
As Of 30 Dec 2013
Search Stocks